Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA: Pazopanib Dose Optimization in RCC
NCT02089802Phase 2Terminated
- Start
- Feb 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC). Primary endpoint: Achievement of plasma trough level > 20 µg/mL by dose escalation in patients with initial level <= 20 µg/mL. Started Feb 2014; status: terminated.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02089802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089802.